The latest insider activity involving Hims & Hers Health, Inc. (NASDAQ:HIMS) centers on its Chief Financial Officer, Oluyemi Okupe. On May 18, 2026, Mr. Okupe sold shares of the company’s Class A Common Stock, totaling an approximate value of $187,915.
The details of this sale indicate that the shares were acquired at prices ranging between $23.55 and $23.80, resulting in a calculated average weighted price of $23.6372 per share. This transaction was not a direct purchase; rather, it followed the exercise of 7,950 stock options that Mr. Okupe had initially acquired at a cost of $5.01 per share, amounting to $39,829 in total.
Crucially, both the option exercise and the subsequent sale were executed under the framework of a Rule 10b5-1 trading plan. This plan was adopted by Mr. Okupe on May 21, 2025.
Market Context and Share Holdings
The timing of this insider divestiture is noteworthy given the current market performance of HIMS stock. Shares are currently trading at $22.44, reflecting a substantial decline of 64% over the past year and a decrease of 10% within the last week alone. Furthermore, the stock exhibits notable volatility relative to the broader market, possessing a beta of 2.42.
Following the recent transactions, Mr. Okupe maintains direct ownership of 262,954 shares of Class A Common Stock. His holdings are further diversified: an additional 7,853 shares are held indirectly through the Oluyemi Okupe Separate Property Trust, which was established on September 1, 2021. Additionally, Mr. Okupe retains 115,900 stock options. These options are fully vested and exercisable, carrying an exercise price of $5.01 per share and expiring on February 23, 2032.
Company Financial Developments
Beyond the insider sales, Hims & Hers Health Inc. recently provided several updates regarding its financial standing and strategic direction. In the first quarter of 2026, the company reported significant earnings that fell short of expectations. Earnings per share stood at -$0.40, missing the forecasted $0.01 target. Revenue also underperformed relative to predictions, reaching $608 million against an anticipated figure of $616.5 million.
In a major financing move, Hims & Hers announced the pricing of a convertible senior notes offering valued at $350 million. This amount represents an increase from a previously planned issuance of $300 million. These notes are scheduled to mature in 2032 and will be sold through a private offering targeted at qualified institutional buyers.
The strategic implications of this capital raise are clear: the proceeds are earmarked to support the company’s international expansion strategy and facilitate the proposed acquisition of Eucalyptus, which is anticipated to close by mid-2026. Furthermore, Hims & Hers plans to dedicate investments toward enhancing its technology and fulfillment infrastructure, with a focus on improving cost efficiencies and advancing AI capabilities.
Analyst Commentary
Industry analysts have also reacted to these developments. Following the announcement of the notes offering, BofA Securities adjusted its price target for Hims & Hers. The firm lowered its previous target from $30 to $28 while maintaining a Neutral rating on the stock.
From an external valuation perspective, analysis conducted by InvestingPro suggests that HIMS currently appears overvalued when compared to its assessed Fair Value. More detailed insights are available through comprehensive Pro Research Reports.